Evidence map›Paper›PMID 36003207›Full record

ArticleJournal of clinical and translational science2022

Screening for participants in the ISCHEMIA trial: Implications for clinical research.

Fatima Rodriguez, Judith S Hochman, Yifan Xu, Harmony R Reynolds, Jeffrey S Berger, Stavroula Mavromichalis, Jonathan D Newman, Sripal Bangalore, David J Maron

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fatima RodriguezDivision of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID https://orcid.org/0000-0002-5226-0723
Judith S HochmanNew York University, Grossman School of Medicine, New York, NY, USA.
Yifan XuNew York University, Grossman School of Medicine, New York, NY, USA.
Harmony R ReynoldsNew York University, Grossman School of Medicine, New York, NY, USA.
Jeffrey S BergerNew York University, Grossman School of Medicine, New York, NY, USA.
Stavroula MavromichalisNew York University, Grossman School of Medicine, New York, NY, USA.
Jonathan D NewmanNew York University, Grossman School of Medicine, New York, NY, USA.
Sripal BangaloreNew York University, Grossman School of Medicine, New York, NY, USA.
David J MaronDivision of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA, USA.

Funding

The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
SURPASS: (Statin Use and Risk Prediction of Atherosclerotic Cardiovascular Disease in minority Subgroups)K01HL144607 · NHLBI · STANFORD UNIVERSITY · PI RODRIGUEZ, FATIMA · 2019 to 2023
$856k
NHLBI NIH HHS K01 HL144607NHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) found that there was no statistical difference in cardiovascular events with an initial invasive strategy as compared with an initial conservative strategy of guideline-directed medical therapy for patients with moderate to severe ischemia on noninvasive testing. In this study, we describe the reasons that potentially eligible patients who were screened for participation in the ISCHEMIA trial did not advance to enrollment, the step prior to randomization. Of those who preliminarily met clinical inclusion criteria on screening logs submitted during the enrollment period, over half did not participate due to physician or patient refusal, a potentially modifiable barrier. This analysis highlights the importance of physician equipoise when advising patients about participation in randomized controlled trials.

Indexed as

Clinical trialsdisparitiesenrollmentscreeningstable ischemic heart disease

Identifiers

PMID36003207
PMCPMC9389278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.